Overview
Selank is a synthetic hexapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is an analog of tuftsin — a naturally occurring tetrapeptide fragment of immunoglobulin G that is produced in the spleen. Selank was designed by extending the tuftsin sequence to improve stability and CNS penetration.
In Russia, Selank is registered as an anxiolytic medication for generalized anxiety disorder and cognitive impairment. It has been studied in Russian clinical settings since the 1990s, though most published research remains in Russian-language journals or has only recently been translated and indexed.
Selank’s profile is notable: it produces anxiolytic effects without the sedation, dependence, or cognitive impairment associated with benzodiazepines — a property that has generated significant interest in the Western nootropic community.
Mechanism of Action
Enkephalin Stabilization: Selank inhibits enkephalinase enzymes that break down naturally occurring enkephalins (endogenous opioid-like peptides). By stabilizing enkephalin levels, Selank enhances the natural anxiolytic and mood-regulating effects of the endogenous opioid system without directly activating opioid receptors.
GABA-A Modulation: Research suggests Selank modulates GABA-A receptor subunit expression — the same receptor system targeted by benzodiazepines — but through a non-benzodiazepine binding site. This may explain anxiolytic effects without tolerance or dependence.
BDNF Upregulation: Selank increases brain-derived neurotrophic factor (BDNF) expression, supporting neuronal plasticity, learning, and memory — mechanisms relevant to its nootropic profile.
Immune Modulation: Like its parent compound tuftsin, Selank modulates IL-2, IL-6, and interferon expression, producing both immunostimulatory and anti-inflammatory effects depending on context.
Clinical Research & Evidence
Evidence Level: 🟠 EL3 — Russian clinical data; limited Western peer-reviewed trials
| Study | N | Finding |
|---|---|---|
| Semenova et al. 2010 | 62 | GAD patients: reduced anxiety scores; no sedation vs. benzodiazepine comparison |
| Zozulya et al. 2001 | Various | Anxiolytic in multiple animal models without benzodiazepine-like dependence |
| Kozlovskaya et al. 2002 | Rat | Enhanced learning; BDNF upregulation confirmed |
Key caveat: The majority of clinical data comes from Russian institutions; independent Western replication is limited. The Russian regulatory approval adds some credibility but does not meet Western RCT standards.
Research-Referenced Dosing Protocols
Intranasal (most common in research):
- 250–3,000 mcg per dose (0.25–3 mg)
- 1–3x daily, typically morning and afternoon (avoid evening to prevent sleep disruption paradox)
- 10–14 day cycle; tolerance appears minimal
Subcutaneous:
- 250–500 mcg subcutaneous injection 1–2x daily
Side Effects & Contraindications
Reported:
- Nasal irritation (intranasal route)
- Mild fatigue at high doses
- Slight emotional blunting in some users (dose-dependent)
Compared to benzodiazepines: No reported dependence, withdrawal, or significant sedation at research doses.
Contraindications (theoretical):
- Pregnancy
- Use with other GABAergic drugs — potential additive sedation
Legal & Regulatory Status
| Region | Status |
|---|---|
| Russia | Registered anxiolytic medication |
| United States | Not FDA approved; research chemical status |
| European Union | Not EMA approved |
Research Citations
- Semenova TP, et al. Effect of Selank on the development and extinction of a defensive conditioned reflex. Bull Exp Biol Med. 2010.
- Zozulya AA, et al. The immunomodulatory and analgesic action of Selank. Neurosci Behav Physiol. 2001.
- Kozlovskaya MM, et al. Anxiolytic and nootropic activity of Selank. Bull Exp Biol Med. 2002.